Rigontec GmbH

Rigontec is a leader in the field of RIG-I-activating RNA therapeutics. Using our proprietary RIG-I agonist platform, we are taking advantage of one of the most important pathways of the innate immune system to develop a novel approach to cancer immunotherapy. Rigontec's proprietary agonists specifically activate RIG-I and provide immediate and long-term anti-tumour immunity. In addition, significant local and systemic tumor regression was demonstrated in several relevant invivo models. Our innovative bifunctional RNA molecules can be developed not only for the treatment of malignant diseases, but also for the treatment of infectious and inflammatory diseases.